Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Solid Biosciences Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHARLESTOWN, MASS., NOV. 04, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 26,550 RESTRICTED STOCK UNITS (RSUS) TO TWO NEWLY HIRED EMPLOYEES.

SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

- DUCHENNE (SGT-003): 23 PARTICIPANTS HAVE BEEN DOSED IN THE INSPIRE DUCHENNE TRIAL AS OF OCTOBER 31, 2025; SOLID EXPECTS TO HAVE DOSED 30 PARTICIPANTS IN TOTAL BY EARLY 2026, THEN PLANS TO MEET WITH THE FDA TO DISCUSS POTENTIAL REGISTRATIONAL PATHWAYS IN H1 2026 - - SGT-003 HAS BEEN GENERALLY WELL TOLERATED USING A STEROID-ONLY PROPHYLACTIC IMMUNOMODULATION REGIMEN; CARDIAC SAFETY MONITORING CONTINUED TO SHOW REDUCTION IN CARDIAC INJURY AND EARLY SIGNALS OF CARDIAC FUNCTION NORMALIZATION - - DAY 90 BIOPSY DATA FROM 10 TREATED PARTICIPANTS (AGES 5-10) SHOWED ALL PARTICIPANTS RESPONDED TO TREATMENT WITH MEAN MICRODYSTROPHIN EXPRESSION OF 58% BY WESTERN BLOT, 58% BY MASS SPECTROMETRY, MEAN MICRODYSTROPHIN POSITIVE FIBERS OF 51% BY IMMUNOFLUORESCENCE, AND MEAN BETA- SARCOGLYCAN POSITIVE FIBERS OF 50% BY IMMUNOFLUORESCENCE - - STRONG STATISTICAL CORRELATIONS OBSERVED BETWEEN DAY 90 MICRODYSTROPHIN EXPRESSION LEVELS AND KEY COMPONENTS OF THE DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX (DAPC), BETA-SARCOGLYCAN (R = 0.95) AND NNOS (R = 0.95), DEMONSTRATED EVIDENCE OF SGT-003-MEDIATED DAPC RESTORATION AND CONCORDANT SIGNALS OF MUSCLE PROTECTION VIA REDUCTIONS IN CK LEVELS (R = -0.78) - - SOLID HAS ACTIVATED THE FIRST CLINICAL TRIAL SITE AND IS CURRENTLY SCREENING PARTICIPANTS FOR IMPACT DUCHENNE, A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EX-U.S. CLINICAL TRIAL OF SGT-003 - - FA (SGT-212): SOLID HAS ACTIVATED THE FIRST CLINICAL TRIAL SITE AND IS CURRENTLY SCREENING PARTICIPANTS FOR FALCON, A PHASE 1B FIRST-IN-HUMAN CLINICAL TRIAL EVALUATING SGT-212 FOR THE TREATMENT OF FRIEDREICH'S ATAXIA - - CPVT (SGT-501): CLINICAL TRIAL SITE ACTIVATION FOR ARTEMIS, A PHASE 1B FIRST-IN-HUMAN CLINICAL TRIAL EVALUATING SGT-501 FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA EXPECTED IN Q4 2025 - - CAPSIDS (AAV-SLB101): OVER 30 AGREEMENTS INCLUDING LICENSES EXECUTED WITH CORPORATIONS, INSTITUTIONS, AND ACADEMIC LABS FOR THE USE OF AAV-SLB101 - - CASH: COMPANY

SOLID BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES UPDATE ON INSPIRE DUCHENNE CLINICAL TRIAL PROGRESS AND PLANNED REGULATORY DISCUSSIONS

CHARLESTOWN, MASS., OCT. 30, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES: 2025 TRUIST SECURITIES BIOPHARMA SYMPOSIUM DR. GABRIEL BROOKS, CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN A PANEL DISCUSSION TITLED PRECISION MEDICINE: DMD, FA, AND BEYOND ON THURSDAY, NOVEMBER 6, 2025, AT 1:40 P.M.

SOLID BIOSCIENCES TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

CHARLESTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 116,150 RESTRICTED STOCK UNITS (RSUS) TO FOUR NEWLY HIRED EMPLOYEES.

CHARLESTOWN, MASS., OCT. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, WILL PRESENT DATA FROM ITS NEUROMUSCULAR AND CARDIAC PROGRAMS AT THE WORLD MUSCLE SOCIETY (WMS) 2025 ANNUAL INTERNATIONAL CONGRESS, OCTOBER 7-11, 2025, IN VIENNA, AUSTRIA, AND AT THE EUROPEAN SOCIETY OF GENE & CELL THERAPY (ESGCT) 2025 ANNUAL CONGRESS, OCTOBER 7-12, 2025, IN SEVILLE, SPAIN.

SOLID BIOSCIENCES TO PRESENT AT UPCOMING SCIENTIFIC MEETINGS

CHARLESTOWN, MASS., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, WILL PRESENT DATA FROM THE PHASE 1/2 INSPIRE DUCHENNE TRIAL EVALUATING SGT-003, A NEXT-GENERATION INVESTIGATIONAL GENE THERAPY INTENDED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DUCHENNE), AT THE 26TH ANNUAL SCIENTIFIC MEETING OF NEUROMUSCULAR STUDY GROUP (NMSG), SEPTEMBER 26-28, 2025, IN STRESA, ITALY. PRESENTATIONS WILL INCLUDE PREVIOUSLY REPORTED DAY 90 BIOPSY DATA IN ADDITION TO UPDATED SAFETY DATA AS OF THE AUGUST 12, 2025, DATA CUTOFF FROM THE INSPIRE DUCHENNE TRIAL.

SOLID BIOSCIENCES TO PRESENT AT 2025 NEUROMUSCULAR STUDY GROUP ANNUAL SCIENTIFIC MEETING

- NON-EXCLUSIVE LICENSE FOR SOLID'S PROPRIETARY, NEXT GENERATION CAPSID, AAV-SLB101, TO ACCELERATE DEVELOPMENT OF KINEA BIO'S GENE THERAPY FOR DYSFERLIN-RELATED LIMB-GIRDLE MUSCULAR DYSTROPHY -

SOLID BIOSCIENCES ANNOUNCES LICENSING AGREEMENT WITH KINEA BIO FOR THE USE OF PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101

SEATTLE--(BUSINESS WIRE)--KINEA BIO INC., A BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING TRANSFORMATIVE GENETIC MEDICINES, TODAY ANNOUNCED TWO MAJOR ACHIEVEMENTS IN ITS GENE THERAPY PROGRAM: A COMMITMENT BY THE JAIN FOUNDATION TO INVEST UP TO $1.1 MILLION BASED ON THE ACHIEVEMENT OF CERTAIN MILESTONES TO SUPPORT CRITICAL PRECLINICAL STUDIES, AND A STRATEGIC LICENSE FROM SOLID BIOSCIENCES FOR ITS PROPRIETARY, NEXT-GENERATION MYOTROPIC AAV CAPSID, AAV-SLB101, TO ENABLE SAFE AND EFFECTIVE MUSCLE-.

KINEA BIO SECURES $1.1M JAIN FOUNDATION INVESTMENT AND SOLID BIOSCIENCES CAPSID LICENSE TO ADVANCE NOVEL GENE THERAPY FOR DYSFERLINOPATHY, A RARE NEUROMUSCULAR DISEASE

CHARLESTOWN, MASS., AUG. 28, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES:

- DUCHENNE (SGT-003): 15 PARTICIPANTS DOSED IN THE PHASE 1/2 INSPIRE DUCHENNE TRIAL AND DOSING REMAINS ONGOING; ON TRACK TO DISCUSS REGULATORY PATHWAYS WITH U.S. FDA IN Q4 2025 -

SOLID BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CHARLESTOWN, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 55,450 RESTRICTED STOCK UNITS (RSUS) TO FOUR NEWLY HIRED EMPLOYEES.

- SGT-501 HAS NOW RECEIVED FDA FAST TRACK, ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS - - POTENTIAL FIRST-IN-CLASS THERAPY WITH FDA IND CLEARANCE AND HEALTH CANADA CTA APPROVAL DESIGNED TO ADDRESS UNDERLYING CAUSES OF CPVT, A LIFE-THREATENING, ARRHYTHMOGENIC CARDIAC CONDITION - - SOLID EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN THE FOURTH QUARTER OF 2025 - CHARLESTOWN, MASS., JULY 23, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A CLINICAL STAGE LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED THAT IT RECEIVED FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR SGT-501, THE COMPANY'S NOVEL, AAV-BASED INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT).

SOLID BIOSCIENCES RECEIVES FDA FAST TRACK DESIGNATION FOR SGT-501 FIRST-IN-CLASS GENE THERAPY FOR CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

Solid Biosciences Inc.

SLDB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Solid Biosciences Inc.

SLDB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SLDB